MLYS Strangle Strategy
MLYS (Mineralys Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS (Mineralys Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.78B, a beta of 0.48 versus the broader market, a 52-week range of 12.59-47.65, average daily share volume of 1.2M, a public-listing history dating back to 2023, approximately 51 full-time employees. These structural characteristics shape how MLYS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.48 indicates MLYS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on MLYS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current MLYS snapshot
As of May 15, 2026, spot at $27.34, ATM IV 93.30%, IV rank 17.25%, expected move 26.75%. The strangle on MLYS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on MLYS specifically: MLYS IV at 93.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a MLYS strangle, with a market-implied 1-standard-deviation move of approximately 26.75% (roughly $7.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MLYS expiries trade a higher absolute premium for lower per-day decay. Position sizing on MLYS should anchor to the underlying notional of $27.34 per share and to the trader's directional view on MLYS stock.
MLYS strangle setup
The MLYS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MLYS near $27.34, the first option leg uses a $28.71 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MLYS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MLYS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $28.71 | N/A |
| Buy 1 | Put | $25.97 | N/A |
MLYS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
MLYS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on MLYS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on MLYS
Strangles on MLYS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MLYS chain.
MLYS thesis for this strangle
The market-implied 1-standard-deviation range for MLYS extends from approximately $20.03 on the downside to $34.65 on the upside. A MLYS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MLYS IV rank near 17.25% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MLYS at 93.30%. As a Healthcare name, MLYS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MLYS-specific events.
MLYS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MLYS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MLYS alongside the broader basket even when MLYS-specific fundamentals are unchanged. Always rebuild the position from current MLYS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on MLYS?
- A strangle on MLYS is the strangle strategy applied to MLYS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MLYS stock trading near $27.34, the strikes shown on this page are snapped to the nearest listed MLYS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MLYS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MLYS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 93.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MLYS strangle?
- The breakeven for the MLYS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MLYS market-implied 1-standard-deviation expected move is approximately 26.75%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on MLYS?
- Strangles on MLYS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MLYS chain.
- How does current MLYS implied volatility affect this strangle?
- MLYS ATM IV is at 93.30% with IV rank near 17.25%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.